Last reviewed · How we verify
NCT06837935
Aluminum Foil Reflector on Phototherapy for Newborn with Jaundice
NA trial testing Aluminum Foil Reflector in Newborn Jaundice in 160 participants. Not yet recruiting.
31 October 2026
Quick facts
| Lead sponsor | Taipei Medical University Shuang Ho Hospital |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 160 |
| Start date | 1 May 2025 |
| Primary completion | 31 October 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- Aluminum Foil Reflector
Conditions studied
- Newborn Jaundice — all drugs for Newborn Jaundice →
Sponsor
Taipei Medical University Shuang Ho Hospital
Who can join
Adults 1 Hour to 14 Days, any sex, with Newborn Jaundice. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Hyperbilirubinemia is defined as the presence of bilirubin in the serum of newborns at levels exceeding the normal range. It is the most common problem among healthy newborns, with an incidence of approximately 40% to 60% in full-term infants. The primary cause is the immature bilirubin metabolism in newborns, leading to the accumulation of excess bilirubin in the blood, which in turn results in a temporary yellowing of the skin and sclera, known as jaundice. Physiological jaundice in full-term newborns typically appears 24 to 72 hours after birth, peaking on days 4 to 5. Studies have shown that neonatal jaundice is a leading cause of readmission after discharge. Phototherapy is the most effective and safest treatment for neonatal hyperbilirubinemia. It takes advantage of bilirubin's sensitivity to light, converting bilirubin into water-soluble conjugated bilirubin, which is then excreted through bile and urine, thereby reducing total bilirubin levels. The most effective light during phototherapy has a wavelength of 400 nm to 520 nm and an intensity of at least 30 microW/cm²/nm, with at least 80% of the infant's body surface area exposed. This study aims to investigate whether using aluminum foil reflective covering around the phototherapy incubator can enhance the effectiveness of light treatment for jaundice in infants, thus potentially reducing the duration of phototherapy required.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06837935
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Newborn Jaundice
Currently open trials in the same condition.
- NCT06498765 — Pacifier Use During Phototherapy in Newborns With Hyperbilirubinemia · NA · active not recruiting
- NCT05282394 — Newborn Abdominal Massage to Prevent Hyperbilirubinemia · NA · active not recruiting
Other Taipei Medical University Shuang Ho Hospital trials
Trials by the same sponsor.
- NCT07380685 — On-Demand AI Support Via LINE-Based GPT Assistant to Improve Emotional Resilience and Reduce Burnout Among Clinical Nurs · NA · not yet recruiting
- NCT07435714 — Facilitating Surgical Choice in Patient With Chronic Hypertrophic Rhinitis Using a Patient Decision Aid · NA · not yet recruiting
- NCT07230366 — Clinical Validation of AI-powered Smart Vehicle Assisted Gait Training in Neurodegenerative Disorders · NA · not yet recruiting
- NCT07257393 — Fall Risk Assessment in Parkinson's Disease Using Kinetikos Health · not yet recruiting
- NCT07192042 — Investigation of Using Non-Wearable Devices to Assess Sleep- Disordered Breathing in Hospitalized Patients With Schizoph · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06837935 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Taipei Medical University Shuang Ho Hospital
- Last refreshed: 26 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06837935.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing